Pfizer and BioNTech have announced that they have completed the application process for approval from the European Medicines Agency (EMA) for the updated vaccine against Covid-19. The vaccine is bivalent and in addition to fighting the old virus it has also been adapted to the Omicron BA.1 sub-variant. The application for approval currently concerns administration to people aged 12 years or older. The data made available in recent weeks by the company and submitted to Ema showed that the new vaccine induced a superior immune response against Omicron BA.1 compared to the vaccine currently on the market.
breaking latest news © Copyright ANSA